Havas posted a 0.8% decline in net organic revenue for 2024, in line with previous guidance from the company. 

The firm reported its full-year 2024 financial results today, the first time it has released results as a publicly traded company since 2017, when it was acquired by Vivendi. 

After a year of planning Havas and several other Vivendi subsidiaries were split off into public companies in December.  

Havas reported record net revenue of 2.7 billion euro (approximately $2.9 billion). That figure includes revenue from acquisitions made last year. The organic number is a “like for like” figure that excludes acquisitions.  

Acquisitions contributed 2.5% to the firm's revenue total last year. The company made 6 M&A deals last year and has already made three this year and company CEO Yannick Bollore said the company would maintain its “dynamic” M&A strategy throughout 2025.  

The company reaffirmed previous guidance that it expects to achieve organic growth this year of 2%+. 

Havas, like Stagwell, considers itself a strong “challenger” alternative to the bigger holding companies. “We are excited about the future and confident in our ability to accelerate in an evolving market,” stated Bollore. 

By region, North America reported the largest organic decline last year, 6.6% including a dip of 3.9% in Q4. The region’s lackluster performance was primarily due to the loss of the Pfizer business early in the year, Havas said, noting that “Havas Media experienced a challenging year in North America in 2024, while Havas Creative recorded a solid performance.”  

Europe grew by 1.2% for the year but was down 2.6% in Q4. The Paris Olympics helped France deliver a “positive performance.” 

APAC showed a modest gain for the year and Latin America was up double digits. 

At its annual meeting in May the company said it would offer several shareholder proposals including a reverse 10-for-1 share split to reduce the number of outstanding ordinary shares.